EU Clinical Trial 2018-003354-24

Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy  Feb 19, 2019

Main objective of the trial: The primary objective of this study is to evaluate the efficacy of cabozantinib in combination with atezolizumab versus sorafenib in subjects with advanced HCC who have not received previous systemic anticancer therapy. An exploratory objective is to evaluate the single-agent activity of cabozantinib in this patient population. El objetivo principal de este estudio es evaluar la eficacia de cabozantinib combinado con atezolizumab frente a sorafenib en pacientes con CHC avanzado que no han recibido ningún tratamiento antineoplásico sistémico anterior. Un objetivo exploratorio es evaluar la actividad de cabozantinib como agente único así como su seguridad en esta población de pacientes.

Parties

Sponsors
Countries
AR AT AU BE BR CA CH CN CO CZ DE ES EU FR GB GE HK HU IE IL IT KR MX NL NZ PH PL RO RU SG TH TR TW UA US
Keywords
ATEZOLIZUMAB Atezolizumab CABOZANTINIB Cabometyx Cabozantinib 20mg Cabozantinib 60mg Nexavar SORAFENIB Sorafenib Tecentriq XL184

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.